You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Accession NumberDB00271  (APRD00913)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA commonly used x-ray contrast medium. As diatrizoate meglumine and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography. [PubChem]
2,4,6-Triiodo-3,5-diacetamidobenzoic acid
3,5-Bis(acetylamino)-2,4,6-triiodobenzoic acid
3,5-diacetamido-2,4,6-triiodobenzoic acid
Acide amidotrizoique
Acidum amidotrizoicum
Acidum diacetylaminotrijodbenzoicum
Amidotrizoic Acid
Amidotrizoic acid (anhydrous)
Diatrizoic acid
Diatrizoic acid (anhydrous)
Methalamic acid
Urografin acid
Urogranoic acid
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Diatrizoate meglumine3X9MR4N98U 131-49-7MIKKOBKEXMRYFQ-WZTVWXICSA-NDetails
Diatrizoate sodiumV5403H8VG7 737-31-5ZEYOIOAKZLALAP-UHFFFAOYSA-MDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CystografinInjection, solution300 mg/mLIntravenousBracco Diagnostics, Inc1970-11-03Not applicableUs
Cystografin DiluteInjection, solution180 mg/mLIntravesicalBracco Diagnostics, Inc1982-11-09Not applicableUs
Hypaque Oral Liquid - 50g/120mlLiquid50 gOral; RectalNycomed Imaging A.S.1997-03-171998-04-21Canada
Hypaque Oral PowderPowder997.4 mgOral; RectalGe Healthcare1998-02-192011-07-27Canada
Hypaque Oral Powder 0.9974g/gPowder997.4 mgOral; RectalSanofi1960-12-311997-07-30Canada
Hypaque Pwr 100%Powder100 %OralSterling Winthrop Inc.1992-12-311996-09-10Canada
Hypaque Sodium 50% - Liq IVLiquid50 %IntravenousNycomed Imaging A.S.1998-04-222000-04-03Canada
Hypaque Sodium 50% LiqLiquid50 %IntravenousSterling Winthrop Inc.1991-12-311996-09-10Canada
Hypaque-M 18%Solution18 %IntravenousAmersham Health1997-08-272006-07-26Canada
Hypaque-M 18% LiqLiquid18 %IntravenousSanofi1979-12-311997-07-30Canada
Hypaque-M 30%Solution30 %IntravenousAmersham Health1998-01-162007-01-11Canada
Hypaque-M 30% LiqLiquid30 %IntravenousSanofi1969-12-311997-07-30Canada
Hypaque-M 60%Solution60 %IntravenousAmersham Health1997-04-162006-12-22Canada
Hypaque-M 60% LiqLiquid60 %IntravenousSanofi1968-12-311997-07-30Canada
Reno-60Liquid600 mgIntravenousBracco Imaging S.P.A.1999-07-012010-01-05Canada
Reno-dipLiquid30 %IntravenousBracco Imaging S.P.A.1998-07-202010-01-05Canada
Reno-M-60Liquid600 mgIntramuscular; IntravenousSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1976-12-311997-08-14Canada
Reno-M-dip Liq 30%Liquid30 %IntravenousSquibb Diagnostics, Division Of Bristol Myers Squibb Canada Inc.1981-12-311998-07-30Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hypaque Oral Liquid 50gm/120mlLiquid50 gOral; RectalSanofi1958-12-311997-07-30Canada
Hypaque Sodium Liq 50%Liquid50 %IntravenousSanofi1954-12-311997-07-30Canada
Unapproved/Other Products Not Available
International Brands
CardiografinNot Available
OdistonNot Available
Brand mixtures
GastrografinBracco Diagnostics, Inc
Gastrografin - Liq OrlBracco Imaging S.P.A.
Gastrografin LiqSquibb Diagnostics, Division Of Bristol Myers Squibb Canada Inc.
Hypaque-M 76%Amersham Health
Hypaque-M 76% LiqSanofi
Hypaque-M Liq 76% USPSterling Winthrop Inc.
Md GastroviewLiebel Flarsheim Company Llc
Md-60Tyco Healthcare
Md-76Tyco Healthcare
Md-76rLiebel Flarsheim Company Llc
Renocal-76Bracco Imaging S.P.A.
Renografin-60 - Liq IVBracco Imaging S.P.A.
Renografin-60 LiqSquibb Diagnostics, Division Of Bristol Myers Squibb Canada Inc.
Renografin-76 - Liq IVBracco Imaging S.P.A.
Renografin-76 LiqSquibb Diagnostics, Division Of Bristol Myers Squibb Canada Inc.
SinografinBracco Diagnostics, Inc
Sinografin - Liq IuBracco Imaging S.P.A.
CAS number117-96-4
WeightAverage: 613.9136
Monoisotopic: 613.769637046
Chemical FormulaC11H9I3N2O4
3,5-diacetamido-2,4,6-triiodobenzoic acid
IndicationUsed, alone or in combination, for a wide variety of diagnostic imaging methods, including angiography, urography, cholangiography, computed tomography, hysterosalpingography, and retrograde pyelography. It can be used for imaging the gastrointestinal tract in patients allergic to barium.
Structured Indications Not Available
PharmacodynamicsDiatrizoate is the most commonly used water-soluble, iodinated, radiopaque x-ray contrast medium. Radiopaque agents are drugs used to help diagnose certain medical problems. They contain iodine, which blocks x-rays. Depending on how the radiopaque agent is given, it localizes or builds up in certain areas of the body. The resulting high level of iodine allows the x-rays to make a "picture" of the area. The areas of the body in which the radiopaque agent localizes will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.
Mechanism of actionDiatrizoate is an iodine-containing X-ray contrast agent. Iodated contrast agents were among the first contrast agents developed. Iodine is known to be particular electron-dense and to effectively scatter or stop X-rays. A good contrast agent requires a high density of electron-dense atoms. Therefore, the more iodine, the more "dense" the x-ray effect. Iodine based contrast media are water soluble and harmless to the body. These contrast agents are sold as clear colorless water solutions, the concentration is usually expressed as mg I/ml. Modern iodinated contrast agents can be used almost anywhere in the body. Most often they are used intravenously, but for various purposes they can also be used intraarterially, intrathecally (the spine) and intraabdominally - just about any body cavity or potential space.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationHowever, it is not metabolized but excreted unchanged in the urine, each diatrizoate molecule remaining "obligated" to its sodium moiety. The liver and small intestine provide the major alternate route of excretion for diatrizoate. Injectable radiopaque diagnostic agents are excreted unchanged in human milk. Saliva is a minor secretory pathway for injectable radiopaque diagnostic agents.
Half lifeNot Available
ClearanceNot Available
ToxicityHigh osmolal radiocontrast agents like diatrizoate are cytotoxic to renal cells. The toxic effects include apoptosis, cellular energy failure, disruption of calcium homeostasis, and disturbance of tubular cell polarity, and are thought to be linked to oxidative stress.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Drug Interactions
DrugInteractionDrug group
AldesleukinThe risk of a hypersensitivity reaction to Diatrizoate is increased when it is combined with Aldesleukin.Approved
MetforminThe risk or severity of adverse effects can be increased when Diatrizoate is combined with Metformin.Approved
Food InteractionsNot Available
Synthesis Reference

Larsen, A.A.; US. Patent 3,076,024; January 29, 1963; assigned to Sterling Drug,Inc.

General ReferencesNot Available
External Links
ATC CodesV08AA01
AHFS Codes
  • 36:68.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.2 KB)
Clinical Trials
Clinical Trials
2, 3CompletedNot AvailableProlonged Postoperative Ileus1
3RecruitingDiagnosticKnown or Suspected Abdominal Disease1
4CompletedDiagnosticHealthy Volunteers1
4CompletedTreatmentMeconium Ileus / Very Low Birth Weight Infant1
4CompletedTreatmentPostoperative Ileus1
  • Bayer healthcare pharmaceuticals inc
  • Bracco diagnostics inc
  • Ge healthcare
  • Mallinckrodt inc
  • Mallinckrodt medical inc
  • Isotex diagnostics
Dosage forms
Injection, solutionIntravenous300 mg/mL
Injection, solutionIntravesical180 mg/mL
LiquidOral; Rectal
LiquidOral; Rectal50 g
PowderOral; Rectal997.4 mg
PowderOral100 %
LiquidIntravenous50 %
SolutionIntravenous18 %
LiquidIntravenous18 %
SolutionIntravenous30 %
SolutionIntravenous60 %
LiquidIntravenous60 %
SolutionIntra-arterial; Intravenous
LiquidIntra-arterial; Intravenous
SolutionOral; Rectal
LiquidIntravenous600 mg
LiquidIntramuscular; Intravenous600 mg
LiquidIntravenous30 %
Injection, solutionIntrauterine
Unit descriptionCostUnit
Gastrografin 66-10 solution0.92USD ml
Hypaque sodium oral powder0.68USD g
Conray 60% vial0.36USD ml
Cystografin 30% infus. btl0.22USD ml
Conray-43 vial0.2USD ml
Conray-30 infusion bottle0.16USD ml
Hypaque 41.66% liquid0.16USD ml
Cystografin-dilute 18% btl0.13USD ml
Cysto-conray 17.2% vial0.11USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Experimental Properties
melting point>250Larsen, A.A.; US. Patent 3,076,024; January 29, 1963; assigned to Sterling Drug,Inc.
logP3.3Not Available
Predicted Properties
Water Solubility0.107 mg/mLALOGPS
pKa (Strongest Acidic)2.17ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area95.5 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity103.13 m3·mol-1ChemAxon
Polarizability38.43 Å3ChemAxon
Number of Rings1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Human Intestinal Absorption-0.8406
Blood Brain Barrier+0.9152
Caco-2 permeable+0.5151
P-glycoprotein substrateNon-substrate0.7998
P-glycoprotein inhibitor INon-inhibitor0.9476
P-glycoprotein inhibitor IINon-inhibitor0.9752
Renal organic cation transporterNon-inhibitor0.9705
CYP450 2C9 substrateNon-substrate0.7632
CYP450 2D6 substrateNon-substrate0.8853
CYP450 3A4 substrateNon-substrate0.6258
CYP450 1A2 substrateNon-inhibitor0.73
CYP450 2C9 inhibitorNon-inhibitor0.8696
CYP450 2D6 inhibitorNon-inhibitor0.94
CYP450 2C19 inhibitorNon-inhibitor0.9271
CYP450 3A4 inhibitorNon-inhibitor0.9376
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9268
Ames testAMES toxic0.508
BiodegradationNot ready biodegradable0.9832
Rat acute toxicity1.9136 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9975
hERG inhibition (predictor II)Non-inhibitor0.9623
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Mass Spec (NIST)Not Available
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
DescriptionThis compound belongs to the class of chemical entities known as halobenzoic acids. These are benzoic acids carrying a halogen atom on the benzene ring.
KingdomChemical entities
Super ClassOrganic compounds
Sub ClassBenzene and substituted derivatives
Direct ParentHalobenzoic acids
Alternative Parents
  • Halobenzoic acid
  • 4-halobenzoic acid
  • 2-halobenzoic acid
  • 4-halobenzoic acid or derivatives
  • 2-halobenzoic acid or derivatives
  • Benzoic acid
  • Benzoyl
  • 1-carboxy-2-haloaromatic compound
  • Halobenzene
  • Iodobenzene
  • Aryl halide
  • Aryl iodide
  • Vinylogous halide
  • Carboximidic acid
  • Carboximidic acid derivative
  • Carboxylic acid derivative
  • Carboxylic acid
  • Organic 1,3-dipolar compound
  • Monocarboxylic acid or derivatives
  • Propargyl-type 1,3-dipolar organic compound
  • Hydrocarbon derivative
  • Organopnictogen compound
  • Organic oxygen compound
  • Organic oxide
  • Organohalogen compound
  • Organoiodide
  • Organonitrogen compound
  • Organooxygen compound
  • Organic nitrogen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:11